检索结果-南通市图书馆

Journal of Geriatric Cardiology 2019年第9期16卷 695-700页

作者： Jian WANG Song-Yuan HE Department of Cardiology Aerospace Central Hospital Aerospace Clinical Medical College of Peking University

Objective To investigate the effect of ramipril on progression of nonculprit lesions in patients with ST-elevation myocardial infarction(STEMI) after primary percutaneous coronary intervention(PPCI). Methods A total of 200 patients(60.1 ± 11.3 years) with STEMI who underwent successful PPCI from January 2010 to December 2013 were enrolled in this study. All patients underwent PPCI as treatment for culprit lesions. Patients were divided into two groups according to the dosage of ramipril used at hospital discharge as follows: high dosage group(2.5–10 mg, q.d.) and low dosage group(1.25–2.5 mg, q.d.). Clinical and angiographic follow-up was performed for 12 months. The primary endpoint was clinically-driven percutaneous coronary intervention(PCI) for nonculprit lesions. The clinical and angiographic features were analyzed. Results Clinical and angiographic follow-up was performed with 87 patients in the high dosage group and 113 patients in the low dosage group. The numbers of patients who underwent additional PCI were six and 20 in the high and low dosage groups, respectively. The rate of having additional PCI performed was lower in the high dosage group than in the low dosage group(6.90% vs. 17.70%, P = 0.03). Conclusions A high dosage of ramipril may prevent progression of nonculprit lesions, which could be the major cause of recurrent PCI in patients with STEMI after PPCI.

关键词： Nonculprit lesion Primary percutaneous coronary intervention ramipril ST-elevation myocardial infarction

Development and validation of an RP-HPLC method for simultaneous determination of ramipril and Amlodipine in tablets

在线全文

学校读者我要写书评

暂无评论

Journal of Pharmaceutical Analysis 2013年第6期3卷 440-446页

作者： Shi-Ying Dai Shi-Ting Qiu Wei Wu Chun-Mei Fu Key Laboratory of Drug Targeting and Drug Delivery System Ministry of EducationWest China School of Pharmacy Sichuan University

AnRP-HPLC method for the simultaneous determination oframipril （RP） andAmlodipine （AL） in tablets was developed and validated by Chinese Pharmacopoeia 2010. The linearity of the proposed method was investigated in the range of 0.01-0.25 mg/mL （r^2=0.9998） for RP and 0.014-0.36 mg/mL （r^2=0.9997） for AL. The limits of detection （LOD） were 0.06 lag/mL and 0.02 μg/mL for RP and AL, and the limits of quantitation （LOQ） were 0.2 Dg/mL and 0.07 μg/mL, respectively. Some major impurities and degradation products did not disturb the detection of RP and AL and the assay can thus be considered stability-indicating.

关键词： ramipril Amlodipine RP-HPLC Stability-indicating

Comparison of cardioprotective effects of mibefradil and ramipril in stroke-prone spontaneously hypertensive rats

在线全文

学校读者我要写书评

暂无评论

Acta Pharmacologica Sinica 2004年第6期 61-66页

作者： Alexander REINECKE,Marc DORENKAMP,Christain STORZ,Havvo BITTERLING,Susanne PENZ,Jack CLEUTJENS,Mat JAP DAEMEN,Reichiger SIMON,Thomas UNGER Institute of Pharmacology University of Kiel 24105 Kiel Germany Institute of Pharmacology University of Kiel 24105 Kiel Germany Clinic of Cardiology Institute of Pharmacology University of Kiel 24105 Kiel Germany Institute of Pharmacology University of Kiel 24105 Kiel Germany University of Kiel Department of Pathology University ofMaastricht Maastricht The Netherlands Clinic of Cardiology University of Kiel 24105 Kiel Germany 24105 Kiel Institute of Pharmacology University of Kiel 24105 Kiel Germany Germany Institute of Pharmacology University of Kiel 24105 Kiel Germany

AIM: To elucidate the cardioprotective effects of T-type calcium channel blocker mibefradil and compare with that of the angiotensin-converting enzyme inhibitor ramipril in a stroke-prone spontaneously hypertensive rats (SHR- SP) model of congestive heart failure (CHF) after myocardial infarction (MI). METHODS: SHR-SP rats were subjected to permanent ligation of the left anterior decending coronary artery. Treatment with mibefradil (10 mg·kg-1·d-1), ramipril (10 mg·kg-1·d-1), or placebo was initiated 4 weeks before surgery and continued up to 6 weeks after induction of MI. Sham-operated rats served as controls. RESULTS: In placebo-treated MI rats, six weeks after MI, left ventricular circumference, inner diameter, and left ventricular end-diastolic pressure (LVEDP) were increased, whereas mean arterial blood pressure (MAP) and maximum rate of rise of left ventricular pressure (dp/ dtmax) were decreased compared with sham-operated controls (Pramipril-treated MI rats, heart weight, heart weight to body weight ratio and interstitial collagen content were reduced (P05), and dp/dtmax was improved (Pramipril-treated MI rats, although interstitial collagen content were reduced (Pramipril diminishes cardiac remodeling of heart failure after MI to a greater extent than mibefradil. Moreover, 6 weeks after MI, mibefradil treatment results in a slight rise in LVEDP compared with placebo-treated rats. Therefore, treatment with mibefradil might be deleterious rather than beneficial compared with ramipril or even placebo treatment in experim

关键词： mibefradil ramipril angiotensin-converting enzyme inhibitors calcium channel blockers myocar- dial infarction heart failure cardiac remodeling ventricular function SHR-SP rats

ramipril在大鼠小肠内转运机制的研究(英文)

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

中国药科大学学报 1993年第6期24卷 338-344页

作者：胡一桥 Tukker Josef 中国药科大学药剂学研究室荷兰乌德勒茨大学药剂学研究室

ramipril是长效ACE(血管紧张素转换酶)抑制剂,它与captopril及enalapril药效学性质相似。文章使用了Ussing Chamber体系对ramipril的小肠转运机制进行了研究。同时研究了头孢菌素(CFX)和乙酰水扬酸(ASA)对ramipril小肠吸收的影响。CFX为... 详细信息

ramipril是长效ACE(血管紧张素转换酶)抑制剂,它与captopril及enalapril药效学性质相似。文章使用了Ussing Chamber体系对ramipril的小肠转运机制进行了研究。同时研究了头孢菌素(CFX)和乙酰水扬酸(ASA)对ramipril小肠吸收的影响。CFX为β-内酰胺类抗菌素,研究已证实其和ACE抑制剂在小肠的转运载体相同。临床实验证明ASA影响ACE抑制剂的药代动力学性质。文章结果表明:ramipril和captopril等ACE抑制剂的肠转运机制有所不同,没有明显的主动转运特点。CFX不抑制ramipril的肠转运。ASA对ramipril的肠转运也没有明显的影响。但是,ramipril确能抑制CFX的肠转运。所以ramipril可能为一个被动吸收的ACE抑制剂,并不依靠小肠的肽载体进行转运。

关键词： ramipril ACE抑制剂吸收

Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2013年第7期126卷 1242-1246页

作者： GUO Jian-qiang WANG Hong-yi SUN Ning-ling Department of Cardiology Peking University People's Hospital Beijing 100044 China

Background Aliskiren is a novel blood pressure-lowering agent acting as an oral direct renin inhibitor. The aim of this study was to assess the effect of aliskiren on arterial stiffness, compared with that of ramipril in mild to moderate essential hypertensive patients. Methods Following a two week placebo run-in period, patients with a mean sitting diastolic blood pressure （ms-DBP）〉95 and 〈110 mmHg （1 mmHg=0.133 kPa）, and a mean sitting systolic blood pressure （ms-SBP）〈180 mmHg were randomly allocated to treatment with aliskiren （150 mg/d, n=20） or ramipril （5 mg/d, n=20） for eight weeks. Blood pressure, plasma renin activity, and the brachial-ankle pulse wave velocity （ba-PWV） were measured before and after eight weeks of treatment. Results Eight weeks of treatment significantly decreased systolic blood pressure and diastolic blood pressure in both the aliskiren group and ramipril group. The hypotensJve effect did not differ between the two groups. Plasma renin activity decreased after aliskiren treatment and increased after ramipril treatment. There was no significant difference in baseline ba-PWV between the aliskiren and ramipril groups （P=-0.892）. The ba-PWV was significantly reduced in both the aliskiren group （1535 （1405-1666） vs. 1464 （1360-1506） cm/s）（P 〈0.01） and the ramipril group （1544 （1433-1673） vs. 1447 （1327-1549） cm/s）（P 〈0.01）. No statistically significant difference was found in the decline of ba-PWV between the two groups （P=0.766）. Conclusions The current study revealed that aliskiren （150 mg/d） could ameliorate arterial stiffness and its effect was similar to ramipril （5 mg/d） in mild to moderate hypertensive patients, indicating that in addition to lowering blood pressure, aliskiren had beneficial effect on vascular protection.

关键词： aliskiren arterial stiffness hypertension ramipril

<i>Low Dose</i>Irbesartan Has a Renoprotective Effect as High Dose ramipril in Diabetic Rats Treated with Insulin

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Endocrine and Metabolic Diseases 2015年第11期5卷 149-161页

作者： Abdulmonim A. Alqasim Sami H. Hammadi Ghazi A. Bamagous Essam Eldin M. Noureldin Hussam H. Madi Department of Physiology Faculty of Medicine Umm-Alqura University Makkah Saudi Arabia Department of Internal Medicine Faculty of Medicine Umm-Alqura University Makkah Saudi Arabia Department of Pharmacology & Toxicology Faculty of Medicine Umm-Alqura University MakkahSaudi Arabia Department of Biochemistry Faculty of Medicine Umm-Alqura University Makkah Saudi Arabia Department of Pathology Faculty of Medicine Umm-Alqura University Makkah Saudi Arabia

Objectives: The aim of this study is to compare the efficacy of the anti-angiotensinic drug, ramipril and irbesartan on the vascular protection of kidneys of streptozotocin (STZ)-induced diabetic rats (DR). Methods: 110 male albino rats were divided into 7 main groups. Group-1 (10 normal control rats;NC). Group-2 (10 rats) was injected intra-peritoneally with STZ (Diabetic Rats;DR). Group-3 (10 DR) is controlled by insulin. Groups 4 to 7 (20 DR), each is subdivided into two subgroups that received either low or high dose of ramipril or irbesartan with or without insulin. Two months post treatment, rat-tail blood was collected to measure: Fasting blood sugar, HbA1c, total serum proteins, albumin and lipid profiles. Urine was collected to measure albuminuria. Kidneys were isolated for histopathological study. Results: Biochemically, both ramipril and irbesartan (without insulin) lowered albumin concentration in urine samples especially at high doses. Histopathologically, there is no beneficial response of both drugs without insulin. Combination of insulin together with either drug has beneficial effects biochemically and histopathologically at high doses. Low dose irbesartan only has renoprotective effect in DR treated with insulin. The other biochemical parameters showed negligible response to both drugs. Conclusion: Low dose irbesartan and high doses of both drugs have renoprotective effect in DR treated with insulin.

关键词： Diabetic Nephropathy Albuminurea ramipril Irbesartan

ramipril的药理学性质及在心血管疾病中的疗效

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

医药月刊 1991年第4期 11-13页

作者：张国祥

Stress Degradation Behavior of a Polypill and Development of Stability Indicating UHPLC Method for the Simultaneous Estimation of Aspirin, Atorvastatin, ramipril and Metoprolol Succinate

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

American Journal of Analytical Chemistry 2011年第4期2卷 401-410页

作者： Satheesh Kumar Shetty K.V Surendranath P Radhakrishnanand Roshan M Borkar Prashant S Devrukhakar Johnson Jogul Upendra Mani Tripathi 不详

A novel, sensitive and precise UHPLC method has been developed and validated for the simultaneous determination of the all the active components of a Polypill viz Zycad, i.e., Aspirin (ASP) Atorvastatin (ATV), ramipril (RMP) and Metoprolol (MTP) in Zycad tablet dosage form in the presence of degradation products. Forced degradation of individual as well as combination of all the drug substances components of Polypill was conducted in accordance with ICH guidelines. Acidic, basic, neutral, and oxidative hydrolysis, thermal stress, and photolytic degradation were used to assess the stability-indicating power of the method. Use of 100 × 2.1 mm, 1.7 μm stationary phases with simple mobile phase combination buffer consisting of 0.1% Perchloric acid (adjusted to pH 2.5) and Acetonitrile, delivered in a gradient mode and quantitation was carried out using ultraviolet detection at 215 nm with a flow rate of 0.6 mL?min–1. The method was optimized using samples generated by forced degradation studies. The method was validated for linearity, accuracy (recovery), precision, Specificity and robustness. The method was linear in the range of 37.5 to 150.0 μg?mL–1 for ASP, 5.0 to 20.0 μg?mL–1 for ATV and 2.5 to 10.0 μg?mL–1 for RMP and 25.0 to 100.0 μg?mL–1 for MTP.

关键词： Liquid Chromatography UHPLC Polypill Aspirin Atorvastatin ramipril And Metoprolol Succinate Forced Degradation Validation Stability Indicating

Effects of ramipril on ventricular arrhythmia after myocardial infarction in rabbits

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Emergency Medicine 2014年第2期5卷 135-138页

作者： Ya Zhong Ping Cao Chuan-feng Tong Xia Li Department of Geratology Zhongnan Hospital of Wuhan University

BACKGROUND： Ventricular arrhythmia （VA） is one of the most common complications of myocardial infarction （MI）, and ventricular tachycardia and fibrillation are the main causes for sudden cardiac death. This study aimed to explore the effect of ramipril on the occurrence of VA and its mechanism after MI in rabbits. METHODS： Twenty-four New Zealand rabbits purchased from the Wuhan Laboratory Animal Research Center were divided into three groups： sham-operated （SHAM） group （n=8）, MI group （n=8） and MI with ramipril （RAM） group （n=8）. Rabbits in the SHAM group received a median sternotomy without ligation of the left ventricular coronary artery. Rabbits in the MI and RAM groups received a median sternotomy followed by ligation of the left coronary artery. The successful anterior MI was confirmed by elevation of the ST segment with more than 0.2 mV in lead II and II1. After MI, rabbits in the RAM group were fed with intragastric ramipril （1 mg/kg per day ） for 12 weeks. Before and 12 weeks after MI in the three groups, ventricular tachycardia or fibrillation （VT/VF） episodes and MAP in cadiocytes of the epicardium, mid-myocardium and endocardium were recorded by a multichannel physiograph. Student＇s t test and ANOVA were used for statistical analysis. RESULTS： VT/VF episodes were decreased more markedly in the RAM group than in the MI group after 12 weeks （2.6±0.8 vs. 12.±＋2.9, P〈0.05）. Twelve weeks after MI, the duration of repolarization for 90% （APD90） of three-tier ventricular myocytes in the MI group was longer than that before MI （258.2±21.1 vs. 230.1±23.2,278.0±23.8 vs. 245.8±25.4,242.6±22.7 vs. 227.0±21.7, P〈0.05）. However, the APD90 was not significantly different at 12 weeks before and after MI in the RAM group （P〉0.05）. Moreover, the transmural dispersion of repolarization （TDR） was increased more markedly 12 weeks after MI in the MI group than in the SHAM and RAM groups （36.2±10.2 vs. 18.7±6.2, 24.9±8.7, P〈0.05）. But the TDR was not significantly different

关键词： Myocardial infarction Ventricular arrhythmia Monophasic action potentia duration Transmural dispersion of repolarization ramipril Rabbits

Effect of ramipril on Renin-Angiotensin-Aldosterone System of Young and Middle-Aged Patients with Hypertension

在线全文

学校读者我要写书评

暂无评论

Journal of Hainan Medical University 2019年第23期25卷 12-16页

作者： Hui-Ling Yuan Xiao-Hua Zhang Yong Tian Rui-Hong Bu Hong-Bin Liu Yan-GeXie Jing Lai Juan Chen Jun-Xia Pan Emergency Department The Third Hospital of Hebei Shijiazhuang 050011 Shijiazhuang City Cardiology The Third Hospital of Hebei Shijiazhuang 050011 Shijiazhuang City

Objective:To explore the effect of ramipril on renin-angiotensin-aldosterone system of young and middle-aged patients with *** 90 young and middle-aged patients with hypertension who had been seeking treatment in the hospital between August 2017 and August 2018 were selected and randomly divided into a control group and an observation group according to the random number table,with 45 cases in each *** control group received Amlodipine for treatment,whereas the observation group was given Amlodipine combined with ramipril for *** hemodynamic indexes,blood lipid,blood pressure,angiotensinⅡ(AngⅡ),plasma renin(PRA),aldosterone(ALD)levels and incidence of adverse reactions during the medication in the two groups were compared before and after *** After treatment,thefibrinogen,plasma viscosity and whole blood viscosity in the observation group were significantly higher than those in the control group,with statistically significant difference between the two groups(Pramipril,which is of high safety,can effectively improve the activity of their renin-angiotensin-aldosterone system,reduce the l

关键词： ramipril Renin-Angiotensin-Aldosterone System Hypertension